Many female patients are concerned about the safety of antidepressants for pregnant women and whether they will cause harm to the fetus or bring about malformations, especially since pregnant women have to go through pregnancy in October and the drugs will enter the fetus through the placenta when the mother is taking the drugs, so many female patients, especially those who are pregnant or preparing for pregnancy, are particularly interested in knowing how harmful antidepressants are to the fetus. This article only analyzes the reproductive toxicity of the most commonly used first-line antidepressants, including 5-hydroxytryptamine reuptake inhibitors (SSRIs) and 5-hydroxytryptamine and norepinephrine reuptake inhibitors (SNRIs) and mirtazapine, as follows: Regarding the reproductive toxicity of SSRIs, 1. There are also no selective embryotoxic effects. Recent epidemiological studies of pregnancy outcomes following first trimester exposure to antidepressants have reported an increased risk of congenital malformations associated with paroxetine use, particularly in the cardiovascular setting (e.g., atrial septal defect), suggesting that the risk of cardiovascular defects in infants of mothers exposed to paroxetine is approximately 1/50, compared with an expected risk of 1/100 in the general population. 2. In animal reproduction experiments, no reproductive impairment or teratogenic effects of high doses of this drug were found. There is a lack of information on clinical aspects. 3, For citalopram, the results of animal experiments showed that the oral administration of citalopram 32, 56, 112mg/kg/day in teratogen-sensitive rats at the highest dose (equivalent to 18 times of MRHD) resulted in embryo/foetus growth inhibition, reduced foetus survival, increased foetus abnormalities (including cardiovascular and skeletal muscle defects) and maternal toxicity, with no effect dose of 56mg/kg/day. day. Oral administration of citalopram to rabbits at doses up to 16 mg/kg/day (equivalent to 5 times the MRHD) did not show any abnormalities. In perinatal rats, oral administration of citalopram at 4.8, 12.8 and 32 mg/kg/day, the highest dose group (5 times the MRHD) showed increased mortality and growth arrest of the pups within 4 days after birth. These results suggest that citalopram causes growth arrest and mortality. 4. Escitalopram, comparable to citalopram, was observed to have teratogenic effects in reproductive toxicology studies in rats, but no increased incidence of teratogenicity was found. Therefore, Lexapro should not be used in pregnant women. 5. Regarding sertraline (Zoloft), sporadic studies on small sample sizes of nursing mothers and infants suggest that although sertraline concentrations in breast milk are higher than those in serum, sertraline concentrations in infant serum are extremely low or undetectable and should be used by nursing women only if the benefits outweigh the harms. Therefore, sertraline is relatively safe and may be considered if it must be used.